The anti-infectives committee will review levofloxacin for the treatment of community acquired pneumonia due to penicillin-resistant S. pneumonia on the afternoon of Oct. 20. The committee will consider development of antimicrobial drugs for the treatment of catheter-related blood stream infections in the morning session, beginning at 9 a.m
You may also be interested in...
The upcoming advisory committee review of a new indication for Ortho McNeil's Levaquin (levofloxacin) could affect Bristol-Myers Squibb's positioning of its pending quinolone antibiotic Tequin (gatifloxacin).
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011